Merck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial
Dateline City:
KENILWORTH, N.J.
Results From C-EDGE Head-to-Head Study in Patients with Chronic Hepatitis C Genotypes 1 or 4 Infection Presented at The International Liver Congress™ 2016
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced the presentation of results from C-EDGE
Head-to-Head, the company’s comparative, Phase 3,
open-label clinical trial evaluating the efficacy and safety of
ZEPATIER™ (elbasvir and grazoprevir) 50mg/100mg tablets versus a regimen
of sofosbuvir 400mg tablets plus peginterferon and ribavirin
(pegIFN/RBV) in treatment-naïve and pegIFN/RBV treatment-experienced
patients with chronic hepatitis C (HCV) genotype (GT) 1 or GT4 infect
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK ZEPATIER Source Type: news
More News: Clinical Trials | Hepatitis | Hepatitis C | Liver | Merck | Pharmaceuticals | Politics | Study | Urology & Nephrology